



GOOD PEOPLE  
*for* GOOD HEALTH

---

September 11, 2023

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code : 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Subject: Press Release**

Enclosed please find press release the Company proposes to issue on publication of its 2<sup>nd</sup> Sustainability (ESG) Report.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For J.B. Chemicals & Pharmaceuticals Limited**

**Sandeep Phadnis**  
**Vice President - Secretarial**  
**& Company Secretary**

**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
**CIN:** L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
**CIN:** L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500



GOOD PEOPLE  
for GOOD HEALTH

## JB PHARMA PUBLISHES ITS 2<sup>ND</sup> SUSTAINABILITY (ESG) REPORT FOR FY 2022-23


- *The report is based on international reporting frameworks with reference to Global Reporting Initiative (GRI) 2021 standards & United Nations Sustainable Development Goals (UN SDGs)*
- *JB Pharma reported 19% decrease in GHG intensity as compared to last year and commenced its journey of Scope 3 emissions accounting towards implementing systematic lowering of overall emissions.*

**Mumbai, 11th September 2023:** J B Chemicals & Pharmaceuticals Ltd (JB Pharma), one of the fastest growing pharma companies in India, today published its 2<sup>nd</sup> Sustainability (ESG) Report. The report reflects JB Pharma's priorities in building sustainable, equitable and resilient systems to promulgate good health for the current and future generations.

While the overall **Green House Gases (GHG) intensity** (i.e. Scope 1 & Scope 2) has been **reduced by 19% as compared to last year**. This financial year also witnessed the completion of **calculating scope 3 emissions** for the first time for JB Pharma, where focus will be on total emissions across the organization and the external supply chain. The initiation of a renewable hybrid power supply (wind & solar) across all manufacturing facilities in India resulted in **8464.89 GJ energy being derived from these sources**.

**Nikhil Chopra, CEO & Whole Time Director, JB Pharma at the launch of the report** said, "ESG is an imperative for progressive businesses operating in a dynamic environment. The 2<sup>nd</sup> report highlights progress made and an action-oriented approach for the next financial year. It is prepared following the international reporting frameworks i.e. **Global Reporting Initiative (GRI)** as its core standard, and linkages with the **United Nations Sustainable Development Goals (UN SDGs)**."

"**People, patients and planet will always remain at the fulcrum** of JB's existence as we constantly evolve and embed responsible practices for a sustainable world. Underpinned by a growth-mindset, robust governance systems and state-of-the-art facilities, JB Pharma is committed towards providing quality and cost-effective medicines across the globe." He added.



**Registered Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

**Corporate Office:**

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500



GOOD PEOPLE  
for GOOD HEALTH

Nearly **forty thousand litres of water was treated** through Effluent Treatment Plants (ETP) and re-used with all **manufacturing sites being zero liquid discharge. 93.6% of non-hazardous waste generated was diverted from disposal and there was 32.4% decrease in hazardous waste sent to landfills.** Materiality assessment were revisited basis which key policies were developed which serve as a driving force for implementing best governance practices across the entire value chain.

As employees are the fulcrum of the organisation bringing goals to fruition, enhancing their holistic well-being is of paramount importance in JB Pharma. In line with organizational ethos, initiatives like **JB Cares – a 360-degree in-house wellness app was introduced** with the aim of amplifying employee physical and mental well-being. A **continuous learning and development framework (I.D.E.A) with innovative leadership development, talent development and upskilling programmes** at various levels of the workforce is underway to stimulate employees' personal as well as organisational goals. The organisation witnessed a 14.4% increase in women representation since 2019-20, with **14% increase in women representation** across fields, historically dominated by their counterparts in the industry. Championing a culture of inclusion and belonging, JB Pharma has initiated drafting of a charter and framework for **Diversity, Equity and Inclusion (DE&I) framework** which helps in nurturing talent and creating equal opportunities in the organization.

With a people centric approach, JB Pharma's CSR interventions continue to positively impact the lives of communities across the geographies. <https://jbpharma.com/esg-sustainability-reports/>

#### About JB Pharma:

J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hypertension segment. Besides its strong India presence, which accounts for majority of its revenue, its other two home markets are Russia and South Africa. In India, the company has 6 brands among the top 300 IPM brands in the country. The company exports its finished formulations to over 40 countries including the USA. Besides supplying branded generic formulations to several countries, it is also a leader in the manufacturing of medicated lozenges. The company ranks amongst the top 5 manufacturers globally in medicated and herbal lozenges. It has 8 state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for lozenges. The manufacturing facilities are certified by leading regulators across the world.

For more details on JB Pharma, please visit [www.jbpharma.com](http://www.jbpharma.com)

#### For more information, please contact:

Mr. Harsh Sheth

MSL Group

Tel: +91 9870631557

Email : [harsh.sheth@mslgroup.com](mailto:harsh.sheth@mslgroup.com)

#### Registered Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Neelam Centre, 'B' Wing, 4<sup>th</sup> Floor, Hind Cycle Road,  
Worli, Mumbai – 400030, T:+91 22 24822222

#### Corporate Office:

J.B. Chemicals & Pharmaceuticals Limited,  
CIN: L24390MH1976PLC019380  
Cnergy IT Park, Unit A, 8<sup>th</sup> Floor, Appa Saheb Marathe Marg,  
Prabhadevi, Mumbai – 400025, T:+91 22 24395200/5500

[www.jbpharma.com](http://www.jbpharma.com)